North America Biopsy Devices Market Set to Reach USD 1.3 Billion by 2033, Driven by Technological Advancements and Rising Cancer Incidence
Renub Research latest report reveals that the North America Biopsy Devices Market is projected to grow from USD 835.19 Million in 2024 to around USD 1,303.45 Million by 2033, expanding at a CAGR of 5.07% from 2025 to 2033. This surge is attributed to the region’s growing healthcare awareness, rise in cancer diagnostics, and a major shift toward minimally invasive procedures.
To know more, please refer to the full report: North America Biopsy Devices Market
Increasing Cancer Burden Fueling Biopsy Device Demand
Cancer is one of the leading causes of death in North America. With the United States expected to record over 2 million new cancer cases by 2025, the demand for accurate and early diagnostic tools has surged. Among women, breast cancer remains the most commonly diagnosed form, pushing the need for advanced breast biopsy solutions. Biopsy devices are essential for cancer detection, classification, staging, and subsequent treatment planning.
As the need for early detection becomes more prominent, particularly for conditions like breast, lung, prostate, and gastrointestinal cancers, biopsy devices have emerged as indispensable tools in the modern diagnostic ecosystem.
Technological Innovation Redefining the Market Landscape
Modern biopsy procedures have witnessed substantial innovation. From vacuum-assisted biopsy systems to robotic biopsy arms and AI-powered imaging integration, technology is reshaping diagnostic precision. Newer systems ensure higher tissue yield, lower patient discomfort, and enhanced real-time image guidance. These innovations reduce false-negative rates and improve clinical outcomes.
Advancements in MRI-guided and stereotactic systems are allowing deeper and more accurate sampling, particularly beneficial in diagnosing tumors in dense tissues like the breast or brain. Integration with digital pathology and machine learning is creating a new paradigm of precision diagnostics.
Favorable Healthcare Expenditure and Insurance Reimbursement Policies
Government initiatives, improved insurance coverage, and high per capita healthcare spending in North America are contributing significantly to the adoption of advanced diagnostic systems. Hospitals and diagnostic labs are increasingly investing in biopsy guidance systems and high-end biopsy guns to improve patient turnaround and procedural efficiency.
Additionally, increased awareness among patients and physicians about preventive healthcare and regular screening programs has positively impacted the biopsy devices market across urban and rural healthcare setups.
Market Segmentation Analysis
By Product Type
Needle-Based Guns
Needle-based biopsy guns dominate the North American market due to their ease of use, precision, and minimally invasive nature. These guns are widely used across breast, prostate, and liver biopsy procedures and are expected to maintain their lead over the forecast period.
Biopsy Guidance Systems
With technological integration, guidance systems have become a backbone of complex biopsy procedures. The use of image-guided systems ensures real-time needle tracking and superior diagnostic yield, especially for lung and prostate biopsies.
Biopsy Needles
These needles vary by gauge and design (core, aspiration, fine needle) and are selected based on organ accessibility. Manufacturers are now designing flexible needles for hard-to-reach areas, including endoscopic and laparoscopic settings.
Biopsy Forceps
Used primarily in gastroenterological and bronchoscopic procedures, biopsy forceps allow physicians to sample superficial lesions in the digestive and respiratory tracts.
Others
This segment includes specialized tools such as vacuum-assisted biopsy systems, localization wires, and robotic arms, which are gaining traction for niche diagnostic applications and precision medicine.
By Application
Breast Biopsy
North America has one of the highest breast cancer screening rates globally. With increasing awareness and routine mammography, the demand for core needle and vacuum-assisted breast biopsies has surged, making this the leading application segment.
Lung Biopsy
Given the rising incidence of non-small cell lung cancers (NSCLC) and increased CT scan-based screening, the lung biopsy segment is expected to grow steadily.
Prostate Biopsy
This segment is driven by an aging male population and the widespread availability of PSA screening programs. MRI/ultrasound fusion-guided biopsies are becoming standard for prostate cancer detection.
Liver Biopsy
Although less frequent than breast or lung biopsies, liver biopsies are critical for diagnosing chronic liver disease, cirrhosis, and hepatocellular carcinoma.
Gastroenterology Biopsy
Endoscopic biopsies for conditions like celiac disease, H. pylori infection, and colorectal cancers contribute significantly to this segment. With growing colon cancer cases, this sub-market is expanding quickly.
Others
Includes kidney, thyroid, bone marrow, and skin biopsies—important for diagnosing hematological or autoimmune conditions.
By Technology
CT Scan Guided
These are particularly useful for deep-seated tumors and lung biopsies. The precision offered by CT guidance reduces the risk of complications.
Stereotactic Guided
This 3D imaging technique is ideal for targeting small lesions and microcalcifications, especially in breast tissue.
Ultrasound Guided
Widely used in soft tissue biopsies (thyroid, liver), ultrasound guidance remains cost-effective and radiation-free.
MRI Guided
Although expensive, MRI-guided biopsies offer unmatched clarity and are preferred in neurology and musculoskeletal applications.
Others
Includes PET-guided and fluoroscopy-guided systems, which are gaining ground for highly localized tumor detection and sampling.
By End User
Hospitals
Hospitals remain the largest end-user segment, handling a vast volume of diagnostic procedures. Large hospitals are integrating automated and robotic biopsy tools into their oncology and radiology departments.
Diagnostic & Imaging Centers
Specialty diagnostic centers are investing in compact, mobile biopsy systems for outpatient use, particularly in urban and semi-urban areas.
Others
This includes ambulatory surgical centers, private clinics, and academic/research institutions exploring new biopsy methods and technologies.
United States Leading the Regional Growth
The United States remains the dominant player in the North American biopsy devices market. This dominance is supported by a high cancer burden, better infrastructure, rising healthcare expenditure, and favorable reimbursement policies.
Additionally, FDA approvals for innovative biopsy devices and strong R&D presence by key market players give the U.S. a clear competitive edge over Canada and Mexico.
Competitive Landscape: A Mix of Innovation and Expansion
Leading players in the North America biopsy devices market are focused on product innovation, strategic acquisitions, and geographical expansion. As demand for minimally invasive diagnostic tools grows, companies are prioritizing precision, efficiency, and safety in product design.
Key Companies Profiled:
- Becton, Dickinson and Company (BD)
- Cook Medical
- Hologic, Inc.
- Cardinal Health
- Boston Scientific Corporation
- Olympus Corporation
- Medtronic plc
- Mammotome
- Inrad Inc.
- Argon Medical Devices
These players are investing heavily in AI-integrated imaging systems, robotic biopsy tools, and personalized biopsy kits to maintain a competitive advantage.
Growth Opportunities and Trends
Artificial Intelligence in Biopsy Diagnostics
AI-based platforms are being tested to assist radiologists and pathologists in identifying malignancies and abnormal cells from biopsy samples faster and more accurately.
Home-Based and Portable Biopsy Kits
With growing demand for remote diagnostics and ambulatory care, there is an emerging trend of portable, handheld biopsy devices tailored for telemedicine.
Expansion into Personalized Medicine
Biopsies are not just for diagnosis anymore. They are now critical for genomic sequencing and personalized cancer therapies, thereby boosting their relevance in advanced oncology care.
Robotic Biopsy Systems
Robotic tools are transforming hard-to-access tumor diagnostics, especially in spine, brain, and abdomen. Their uptake is rising in top-tier hospitals across North America.
Challenges in the Market
Despite rapid growth, the market faces challenges such as:
- High cost of advanced devices
- Shortage of skilled radiologists
- Limited penetration in rural/remote areas
- Patient discomfort and anxiety during procedures
Overcoming these barriers through innovation, training, and awareness will be key to unlocking future market potential.
Future Outlook
The North America biopsy devices market is poised for accelerated growth through 2033. Factors like aging population, rising lifestyle diseases, early cancer screening programs, and technological breakthroughs are creating a fertile ground for long-term expansion.
As stakeholders align their strategies with the evolving demands of diagnostic medicine, biopsy devices will continue to be a vital component in the healthcare diagnostics value chain.
About the Company
Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions.
We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.
Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
